New strategies to enable CAR T cells to overcome the major hurdles in solid tumors – CRI

Cancer Research Institute (CRI) shared on LinkedIn:

“While CAR T cell therapy has made transformational progress for some hematological malignancies, it has yet to make a significant impact on solid tumors, CRI Lloyd J. Old STAR Dr. Paul Beavis of University of Melbourne, Peter MacCallum Cancer Centre explains. In 2025, Dr. Beavis will take his CAR T therapy to a phase 1 clinical trial.

“Our major focus is to devise new strategies to enable CAR T cells to overcome the major hurdles to success in solid tumors: failure to persist, tumor-induced immunosuppression, tumor-antigen heterogeneity, and the challenge of trafficking to a solid tumor site,” he describes. Read more.”

Source: CRI/LinkedIn